# Wall Street's Wildest Stock Showdowns: Bulls vs. Bears!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-10-01T02:10:01.971Z
Source: https://newsyai.com/edition/f4cb6986-afcf-48ec-80ba-8965b1ab3473
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Wall Street's Most Polarizing Shitshows: 3 Stocks Where Bulls and Bears Are Throwing Hands (and Maybe Some Feces) — Fresh Edition, October 1, 2026**

Futures mixed—Dow flat, Nasdaq mainlining the AI hype like it's the fountain of youth, crude oil bouncing like a caffeinated squirrel on a trampoline. Last round's rental fleets, homebuilders, and apparel revivals? Yesterday's news. These three tickers have the Street more divided than a crypto bro at a family reunion. Elevated short interest across the board (flirting with 32-50%+ of float in recent screens, with days-to-cover that screams volatility potential), fresh short data, filings, and chatter only—no reruns. Bulls see structural tailwinds and squeeze fuel; bears see execution flops, dilution landmines, competition overhangs, and fading relevance. Then the first-principles hammer drops.[[1]](https://www.findmymoat.com/short-interest)[[2]](https://www.benzinga.com/short-interest/most-shorted)

### 1. KPTI (Karyopharm Therapeutics) – Oncology Pipeline Rocket or Cash-Burning Biotech Bust?
KPTI sports elevated short interest (~35-41% of float in recent data, with days-to-cover around 5+), as the biotech player advances its XPO1 inhibitor pipeline amid clinical and funding debates.[[1]](https://www.findmymoat.com/short-interest)[[3]](https://altindex.com/ticker/kpti/short-interest)

**Bull Case (The "Pipeline Progress, Approval Catalysts, and 'This Drug Actually Works' Crew")**  
Bulls highlight any positive clinical data or regulatory wins in oncology indications, expanding market for targeted therapies, potential partnerships or buyout interest, and analyst price targets implying significant upside. Some see it as a high-conviction binary play with short interest as squeeze ammo on strong trial readouts or financing success. Institutional support or favorable data could light the fuse.

**Bear Case (The "Relentless Cash Burn, Dilution Risks, Competition from Bigger Players, and 'Will It Ever Turn Profitable?' Crew")**  
Bears hammer ongoing losses, frequent equity raises diluting shareholders, intense rivalry in the oncology space, historical execution misses, and doubts that the pipeline justifies the valuation or risk amid a tough biotech funding environment. Short buildup reflects skepticism that the setup justifies the exposure amid operational and financial risks.[[4]](https://stocknear.com/stocks/KPTI/statistics/short-interest)

**My First-Principles Take**: Biotech value accrues to companies with differentiated mechanisms addressing unmet needs, clear paths to approval and commercialization, efficient capital use or non-dilutive funding, and defensible IP—economics reward clinical execution and market adaptation over pure pipeline bets in a regulation-, competition-, and capital-intensive field. KPTI has genuine tailwinds from its core technology and any data momentum, but durable shareholder value only comes if trials succeed without endless resets, differentiation holds vs. rivals, and operations convert science to revenue without perpetual dilution. The biotech bet is directionally exposed to medical needs, yet it's a capital-, execution-, and sentiment-sensitive play prone to volatility and binary swings. At these short levels, volatility grenade—positive catalysts roast shorts; stumbles feed the fire. High-risk, high-reward for the bold.

### 2. ONDS (Ondas Holdings) – Defense Drone/Autonomous Systems Play or Dilution-Fueled Tech Flop?
ONDS carries notable short interest (~40%+ of float in recent screens, with days-to-cover around 3-4+), as the comms/autonomous systems player navigates defense tailwinds, acquisitions, and execution challenges.[[1]](https://www.findmymoat.com/short-interest)[[5]](https://www.s3partners.com/articles/ondas-huge-short-interest-crowds-onds)

**Bull Case (The "Defense Spending Boom, Order Backlog, Unmanned Systems Demand, and 'Rail/Drone Infrastructure Wins' Crew")**  
Bulls point to surging demand in defense, counter-UAS, and autonomous tech, any progress on revenue scaling or integration of acquisitions, expanding order book and program wins, and broader sector tailwinds from government priorities. Some see it as a high-conviction growth story with short interest hinting at squeeze potential on positive catalysts or contract momentum.

**Bear Case (The "Cash Burn Inferno, Equity Dilution Risks, Integration Headaches, and 'Will Revenue Ever Translate to Profits?' Crew")**  
Bears cite deep unprofitability and high cash consumption, risks of cost overruns or failed integrations, intense competition, historical execution misses, and doubts that the setup justifies exposure amid macro and sector pressures. Short buildup reflects skepticism that hype justifies the risk amid operational and market risks.[[6]](https://seekingalpha.com/news/4638573-ondas-short-interest-surges-to-42-of-float-keeping-squeeze-risk-persistent)

**My First-Principles Take**: Autonomous/defense tech value accrues to operators with scalable tech addressing real security/infrastructure needs, efficient integration of capabilities, adaptable product mix, strong balance sheets or patient capital, and clear routes to predictable cash flow—economics reward execution discipline and market adaptation over pure demand bets in a capital-, competition-, and regulation-intensive field. ONDS has genuine tailwinds from defense trends and backlog momentum, but durable profits only come if builds scale without endless resets, differentiation sticks vs. rivals, and operations deliver positive free cash flow. The tech bet is directionally exposed to security needs, yet it's a capital-, execution-, and sentiment-sensitive play prone to volatility and binary swings. At these short levels, volatility rocket fuel—catalysts roast bears; weakness feeds the fire. High-risk, high-reward for the bold.

### 3. GRPN (Groupon) – AI-Powered Deals Comeback or Legacy Retail Relic?
GRPN features elevated short interest (~32-50%+ of float in various recent screens, with days-to-cover stretching to 14+ in spots), as the deals platform advances amid turnaround efforts and retail shifts.[[1]](https://www.findmymoat.com/short-interest)[[7]](https://curvedtrading.com/stocks/grpn/)

**Bull Case (The "AI Transformation, FCF Generation, Merchant Network Revival, and 'Next Chapter Leader' Crew")**  
Bulls highlight any revenue stabilization or acceleration from AI-driven personalization and new tools, progress toward positive free cash flow, broader local commerce demand, and potential for margin expansion or strategic shifts. Some see it as a high-conviction turnaround story with short interest as squeeze fuel on continued beats or retail wins.

**Bear Case (The "Intense Competition from Bigger Platforms, Merchant/Enterprise Weakness, Margin Pressures, and 'Will Growth Translate to Sustainable Profits?' Crew")**  
Bears hammer rivalry from tech giants and alternatives, slow path to meaningful profitability or market share gains, historical execution misses in deals, valuation multiples leaving little room for error, and doubts that the pipeline justifies the risk/reward amid a tough retail environment. Short buildup reflects skepticism that hype justifies the exposure amid brand and financial risks.[[8]](https://altindex.com/ticker/grpn/short-interest)

**My First-Principles Take**: Deals/e-commerce platforms value accrues to companies with differentiated discovery addressing real consumer/merchant needs, scalable go-to-market and distribution, efficient capital use or path to positive cash flow, defensible network effects, and clear routes to predictable revenue—economics reward product-market fit and capital discipline over pure growth bets in a competition-, trend-, and margin-intensive field. GRPN has genuine tailwinds from local commerce and potential AI momentum, but durable shareholder value only comes if adoption scales without endless resets, differentiation holds vs. incumbents, and operations convert brand to revenue without perpetual promotions or dilution. The retail bet is directionally exposed to lifestyle shifts, yet it's a capital-, execution-, and competition-sensitive play prone to volatility and multiple compression. At these short levels, volatility grenade—positive catalysts roast shorts; weakness feeds the fire. High-risk, high-reward for the bold.

There you have it—three fresh brawls proving disagreement is the market's favorite drug. Do your own damn homework, size like an adult, and remember: the tape stays irrational longer than your margin account can breathe. Sources pulled from latest short interest data (e.g., via Benzinga, TipRanks, FindMyMoat, S3 Partners, thetrading.tools, CurvedTrading, and related screens), company filings/press releases, analyst notes, and options flow as of late September/early October 2026. Trade responsibly, you magnificent animals.
